{"entity":{"id":"avenger-500","kind":"trial","name":"AVENGER 500","aka":[],"tldr":"Adding the metabolism drug devimistat to FOLFIRINOX did not help people with metastatic pancreatic cancer live longer.","summary":"AVENGER 500 was an open-label phase 3 trial in previously untreated metastatic pancreatic adenocarcinoma comparing modified FOLFIRINOX with devimistat against modified FOLFIRINOX alone. The primary endpoint was overall survival. The trial did not show a survival benefit, and response rates were similar between arms, closing the pancreatic programme for devimistat.","status":"negative","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT03504423","url":"https://clinicaltrials.gov/study/NCT03504423"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["devimistat","folfirinox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03504423","phase":"3","setting":"Untreated metastatic pancreatic adenocarcinoma: modified FOLFIRINOX with or without devimistat","sponsor":"Rafael Pharmaceuticals (Cornerstone)","result":"No overall survival benefit from adding devimistat to modified FOLFIRINOX.","yearReported":2024,"outcomes":[]},"route":"/trials/avenger-500/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"devimistat","kind":"drug","name":"Devimistat","route":"/drugs/devimistat/"},{"id":"folfirinox","kind":"drug","name":"FOLFIRINOX / mFOLFIRINOX","route":"/drugs/folfirinox/"}]}}